Home
MOMA Therapeutics

MOMA Therapeutics Market Share Analysis for July 2026

The advent of precision medicine has catalyzed a sea change in biopharmaceutical research and development, leading to significant improvements in patient lives. Today’s translational research involves high-resolution and unbiased approaches to...

Industry: N/A

Domainmomatx.com

Year Founded2019

Employees51 - 200

Annual Revenue$2M - $5M

MOMA Therapeutics

MOMA Therapeutics (including company regionals)

momatx.com

See more website traffic and engagement information

MOMA Therapeutics Revenue up to July 2026 is 2M - 5M

revenue generated by MOMA Therapeutics top domains

MOMA Therapeutics top domains revenue over 3 years

Revenue for MOMA Therapeutics top domains

momatx.com2M - 5M

See more with Sales Intelligence

Total visits to MOMA Therapeutics's top domains

Understand MOMA Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

momatx.com2.9K

See more with Sales Intelligence

Avg. visit duration in MOMA Therapeutics's top domains

Analyze MOMA Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

momatx.com00:00:20

See more with Sales Intelligence

Avg. pageviews on MOMA Therapeutics's top domains

See how MOMA Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

momatx.com1.27

See more with Sales Intelligence

MOMA Therapeutics top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by MOMA Therapeutics

These are the website technologies, by industry, used by MOMA Therapeutics top domains

Conversion & Analytics (3)

Google Analytics

Content Management System (2)

WordPress

Payment & Currencies (2)

Visa

Advertising (1)

PubMatic

More Technologies

7

See all

News & Signals from MOMA Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsWaller leaves Momatx as Vice President, Nonclinical and CMC development.Dr. Waller joins Ajax from MOMA Therapeutics where he was Vice President, Nonclinical and CMC development and responsible for all nonclinical and CMC activities for the company's small molecule portfolio, including two development candidates that advanced to the clinic.

NewsMomatx attended event American Association for Cancer Research Annual Meeting 2025 on Apr 17th '25.CAMBRIDGE, Mass., April 17, 2025 - MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced three poster presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting, being held April 25 - 30, 2025 in Chicago, IL.

NewsMomatx is developing PARP1 inhibitor in homologous recombination-deficient solid tumors.MOMA Therapeutics to develop new PARP1 inhibitor in homologous recombination-deficient solid tumors.